Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors. (2022)

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41467-022-32436-4

PubMed Identifier: 35970853

Publication URI: http://europepmc.org/abstract/MED/35970853

Type: Journal Article/Review

Volume: 13

Parent Publication: Nature communications

Issue: 1

ISSN: 2041-1723